XML 41 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Acquisition of CyDex (Details) - Cydex Pharmaceuticals, Inc - Contingent Consideration Classified as Equity
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Credit Derivatives [Line Items]    
Revenue volatility (as a percent) 25.00% 25.00%
Average probability of commercialization (as a percent) 12.50% 12.50%
Market price of risk 0.029 0.029